AnPac Bio's First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar FundsGlobeNewsWire • 06/18/21
AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests CompletedGlobeNewsWire • 05/27/21
AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample DatabaseGlobeNewsWire • 05/25/21
AnPac Bio-Medical Science Co., Ltd. (ANPC) CEO Dr. Chris Yu on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/01/21
AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss)GlobeNewsWire • 04/30/21
AnPac Bio to Report Fiscal Year 2020 Financial Results on Friday, April 30, 2021GlobeNewsWire • 04/27/21
AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020GlobeNewsWire • 04/16/21
AnPac Bio Developed and Completed Evaluations of New Generation Cancer Detection Sensor with Improved PerformanceGlobeNewsWire • 03/09/21
China's NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)GlobeNewsWire • 02/08/21
AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer DetectionGlobeNewsWire • 02/01/21
AnPac Bio Makes Significant Progress in Detecting Pre-cancer Diseases and Recorded Over 20 Types of Pre-cancer DiseasesGlobeNewsWire • 12/14/20